Propafenone Hydrochloride Capsule, Extended Release
Product Images NDC 16571-736

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Propafenone Hydrochloride (NDC 16571-736). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Rising Pharma Holdings, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

225mg 60ct Label (225mg 60ct Label)

Label for Propafenone Hydrochloride Extended-Release Capsules, USP 225 mg by Rising Pharma Holdings, Inc. The label shows a pack size of 60 capsules. It includes storage, dosage, and handling instructions, as well as manufacturer details and a barcode. The label prominently states "Rx Only."*

FDA Label Image

325mg 60ct Label (325mg 60ct Label)

Label for Propafenone Hydrochloride Extended-Release Capsules USP, 325 mg strength, in a bottle containing 60 capsules. The product is labeled for oral use, prescription only, and manufactured by USV Private Limited. It includes storage and handling instructions, distributor information for Rising Pharma Holdings, Inc., and an NDC barcode.*

FDA Label Image

425mg 60ct Label (425mg 60ct Label)

Label for Propafenone Hydrochloride Extended-Release Capsules, USP 425 mg by Rising Pharma Holdings, Inc. The label indicates a package containing 60 capsules, for oral administration. It includes dosage strength, quantity, and manufacturer details, along with typical storage and safety warnings.*

FDA Label Image

Logo (Logo1)

FDA Label Image

Chemical Structure (Propafenone 01)

Chemical structure diagram of Propafenone Hydrochloride, showing its molecular composition including aromatic rings, ether, hydroxyl, and hydrochloride components as depicted in the image.*

FDA Label Image

Figure 1 (Propafenone 02)

A Kaplan-Meier survival curve graph showing the proportion of patients without event over approximately 300 days. The graph compares Placebo with three dosage groups of Propafenone Hydrochloride extended-release capsules (225 mg, 325 mg, and 425 mg, each taken twice daily). Patient counts at risk are provided for Rythmol SR and Placebo groups at several time points. Statistical significance levels (p-values) are noted for differences between groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.